Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma

NCT03741244 is registered in ClinicalTrials.gov with The Second Hospital of Hebei Medical University as lead sponsor.

NCT NCT03741244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03741244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma
Lead sponsor
The Second Hospital of Hebei Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
May 6, 2019
Completion date
February 28, 2023
Enrollment
211 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma